Home » ADVAXIS' LISTERIA CANCER VACCINE GETS REGULATORY APPROVAL
ADVAXIS' LISTERIA CANCER VACCINE GETS REGULATORY APPROVAL
Advaxis has announced that regulators have allowed the company to initiate Phase I/II clinical testing with its lead compound, Listeria-based cancer vaccine, Lovaxin C. Lovaxin C, which specifically targets cervical cancer in women, will be tested for the first time in humans in this study.
Lovaxin C is a therapeutic designed to treat women who have developed cervical cancer as a result of an HPV infection. Preclinical data for Lovaxin C demonstrates an extremely robust immune response to tumors upon administration of the drug and eradication of tumors in more than half of the animals tested.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May